Cansativa Financial Model
Health-tech Startup Financials (Free Excel Download)
B2B cannabis distribution and ecosystem platform enabling dispensaries, suppliers, growers, and governments to operate in regulated cannabis markets.
professionals from Deloitte
Used by professionals from
About this model
Cansativa is a B2B cannabis distribution and ecosystem platform for regulated markets, connecting suppliers, growers, dispensaries, pharmacies, and governments. It focuses on the operational infrastructure required to move medical cannabis compliantly.
Current revenue comes primarily from import and wholesale distribution, supported by an exclusive government contract for domestic German medical cannabis. A broader platform layer can add services, but product volume and spread remain the core economics.
The model should forecast kilograms distributed, wholesale price, product cost, contract minimums, and gross margin by channel. Inventory, working capital, regulatory compliance, and government-contract concentration should be separated from any future platform fees.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
About Cansativa
cansativa.com
How to build a detailed financial model for Cansativa
A complete walkthrough of the business, drivers, and assumptions behind the downloadable Cansativa model - distilled from its pitch deck and publicly available information.
Product & value proposition
- Platform that handles licensing, regulatory compliance, supply/procurement, and distribution on behalf of cannabis dispensaries and B2B partners.
- Exclusive/monopolist partner of the Federal Republic of Germany for domestic medical cannabis distribution for the next four years.
- Three target verticals: (1) Health / medical, (2) Narcotics/pharmaceutical warehousing and distribution, (3) Wellbeing, food & retail.
- Positioning as the "360° holistic cannabis ecosystem" - connecting suppliers, dispensaries, growers, and governmental bodies.
Market
- German legal medical cannabis market 2021: 15 tons.
- German illegal cannabis market 2021: >400 tons.
- Post-legalization annual addressable cannabis market (Germany, 24–36-month horizon): >4bn EUR.
- European context: 750mn population, >13 trillion EUR economic power.
- Comparable market reference: Colorado (5mn people) generated $2.3bn in cannabis sales in 2021. Germany (83mn people, GDP $3.84 trillion) implies materially larger potential.
- >10bn EUR narcotics services market in Europe.
- No SAM/SOM breakdowns or Cansativa's specific share targets provided.
Revenue model
- Primary current revenue: Import and wholesale distribution of medical cannabis to pharmacies, dispensaries, and healthcare providers (B2B). Earns a margin on product sold (volume × price spread).
- Exclusive government contract for distribution of domestic German medical cannabis - guaranteed offtake for 4 years.
- Platform/ecosystem layer implied (technology, compliance, partner onboarding) - SaaS or take-rate revenue model hinted at but not quantified.
- Recreational market anticipated as a second revenue stream post-legalization; investment slide separates MEDICAL (Scale and Grow) and RECREATIONAL (Prepare) spend.
- No pricing, take rates, or per-unit margins disclosed in deck.
Traction & metrics
- Revenue: Bar chart (slide 10) shows FY2018–FY2021 actuals with clear upward trajectory and steeper planned growth FY2022–FY2025. No absolute EUR values labeled on chart axes - cannot read specific figures.
- Described as having a "proven track record of significant top-line revenue growth and efficient capital allocation".
- "Recurring thousands of customer interactions" referenced as market positioning evidence.
- No customer count, revenue figures (EUR), GMV, or retention rate provided in extractable text or legible chart labels.
Competition / moat
- Moat 1: Government exclusivity - monopolist/exclusive partner of the Federal Republic of Germany for domestic medical cannabis distribution for 4 years.
- Moat 2: First-mover in a highly regulated, licensed market - very high regulatory barriers to entry.
- Moat 3: Broadest product portfolio and established supplier/customer relationships.
- No named competitors referenced; competitive landscape slide not present.
Team & funding ask / use of funds
- Team description: "Top-notch leadership with a proven track record as first-mover in highly regulated & licensed industries and to scale a cannabis business in Europe". No named individuals, bios, or org chart shown.
- Funding ask: $15mn USD.
- Use of funds split into two buckets:
- MEDICAL - Scale and Grow: (1) Double headcount in IT/technology, sales, operations; (2) Connect further B2B-platform partners (suppliers, customers); (3) Platform user acquisition and marketing.
- RECREATIONAL - Prepare: Technology and platform advancement for anticipated recreational market.
Recommended financial model
- Archetype + why: B2B Distribution / Wholesale Revenue model with a Platform Ecosystem overlay. Core revenue driver is volume-based (kg/tons of cannabis distributed × wholesale margin), supplemented by a government contract fixed/minimum offtake and a nascent platform fee layer. This is not SaaS and not pure marketplace GMV - it is closer to a specialty pharmaceutical distributor P&L with a regulatory monopoly wedge. A 3-statement model is appropriate given the capital raise and need to show EBITDA path.
- Forecast horizon & granularity: FY2022–FY2025 (4 years), matching the deck's own outlook period. Annual granularity for the base model; monthly for the first 12 months (cash management given the raise). Medical and Recreational modeled as separate segments.
- Key drivers & assumptions:
- Medical cannabis volume distributed (tons/year): FY2021 baseline ~15 tons German legal market; assume Cansativa captures 60–80% of legal market given exclusive government contract.
- Wholesale price per kg:.
- Distribution/wholesale gross margin %:.
- Platform/ecosystem fee revenue:.
- Headcount growth: double within "next months" per the raise plan; model 2× headcount in FY2022 then linear growth thereafter.
- OpEx: Sales & marketing, IT/tech, operations grow in line with headcount.
- Recreational revenue: zero until post-legalization; model as a scenario toggle starting FY2024.
- CapEx: Minimal (asset-light platform); warehouse/logistics may require some.
- German market post-legalization size: >4bn EUR TAM; Cansativa addressable share.
- Scenarios (Base / Bull / Bear - which variables flex):
- Base: Medical monopoly contract sustained at 60% market share; recreational legalization by 2024; platform fees ramp from 2023.
- Bull: Legalization accelerates (early 2023); Cansativa wins dominant recreational distribution; rapid EU geographic expansion; margin expansion from platform mix shift.
- Bear: Legalization delayed beyond 2025; medical market competition increases post-exclusivity; margin compression from regulatory pricing controls.
- Required sheets / outputs:
- Assumptions (all drivers in one place, toggle for scenarios)
- Medical Segment P&L (volume × price × margin)
- Recreational Segment P&L (gated by legalization trigger)
- Platform/Ecosystem Revenue build
- Headcount & OpEx schedule
- Consolidated P&L (Revenue → EBITDA → EBIT)
- Cash Flow & Runway (linked to $15mn raise)
- Balance Sheet (light - mainly working capital and cash)
- KPI dashboard: Revenue (EUR), Volume (tons), Gross Margin %, EBITDA %, Runway (months)
Frequently asked
Is the Cansativa financial model free?+
Yes. The Cansativa model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.
What's included in the model?+
A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.
How was this model built?+
It was built from Cansativa's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.
Can I change the assumptions?+
Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Health-tech Startup Financial Models
Browse another startup in the same category.
98point6
B2B SaaS platform licensing an AI-powered virtual care technology stack to health systems, pivoted from running a direct-to-employer virtual clinic.
A-Champs
IoT-powered gamified training device (ROXs PRO) for sports/health professionals, evolving into a B2C smart coach app for families.
AccuRx
Patient-centred communication platform connecting everyone involved in a patient's care, starting with near-universal penetration in UK GP practices.
Aeris
Swiss-made premium air purifiers sold through DTC, retail, and dealer channels, with a recurring filter consumable attached to a connected mobile app.
Akido Labs
Akido Labs is a data-driven prevention platform that integrates siloed healthcare, municipal, and non-profit data to enable proactive outreach and case management for vulnerable populations (homeless, chronically ill, etc.).
Alloy
Telehealth + DTC subscription platform delivering menopause hormonal treatment (MHT) and holistic care to U.S. women 40+.
Astek Diagnostics
Point-of-care diagnostic device (Jiddu system) that confirms bacterial infections and antibiotic sensitivity in ~1 hour across four body fluid types (urine, CSF, effluent, blood).
Atom Limbs
Atom Limbs is building the first AI-powered, neural-controlled prosthetic arm sold direct-to-consumer on a subscription model.
